Methods and materials for identifying and treating membranous nephropathy
US-2024353404-A1 · Oct 24, 2024 · US
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US9068005B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9068005-B2 |
| Application number | US-40934909-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 23, 2009 |
| Priority date | Apr 20, 1998 |
| Publication date | Jun 30, 2015 |
| Grant date | Jun 30, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating B-cell lymphoma in a mammal comprising administering to said mammal a therapeutically effective amount of a glycoengineered IgG antibody to CD20, wherein said glycoengineered antibody is obtained from a host cell that has been genetically manipulated to have altered activity of at least one glycoprotein-modifying glycosyltransferase, wherein said antibody has an altered pattern of N-linked oligosaccharides in the Fc region compared to th…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9068005B2 cover?
- The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cell…
- Who is the assignee on this patent?
- Umaña Pablo, Jean-Mairet Joël, Bailey M Sean, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2887. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).